Загрузка...
New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Russo |
| Опубликовано: |
IMA-PRESS LLC
2021-10-01
|
| Серии: | Научно-практическая ревматология |
| Предметы: | |
| Online-ссылка: | https://rsp.mediar-press.net/rsp/article/view/3072 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|